Why is Par Drugs & Che. falling/rising?

As of 26-Sep, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 104.06, which reflects a decrease of 4.42 or 4.07%. The stock has underperformed its sector by 2.08% today, and while it is trading above its 50-day and 100-day moving averages, it is below its 5-day, 20-day, and 200-day moving averages. Over the past week, the stock has dropped by 7.64%, and its year-to-date performance shows a significant decline of 47.68%. The company has faced negative results for the last three consecutive quarters, with a reported profit after tax decline of 20.32% in the latest six months, contributing to the stock's poor performance.
In the broader market context, the BSE Small Cap index has also fallen by 2.05%, indicating a challenging environment for small-cap stocks. Compared to the benchmark Sensex, which has seen a decline of 2.65% over the past week, Par Drugs' performance is notably worse. The company's long-term growth prospects appear weak, with net sales growth at only 12.10% annually over the last five years and an operating profit growth of just 1.10%. Despite a low debt-to-equity ratio and an attractive valuation, the significant drop in stock price over the past year, at 57.03%, suggests that investor sentiment remains negative, particularly in light of the company's declining profits and underperformance relative to the broader market.